Literature DB >> 18398362

Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study.

Stephen J Kim1, Neal A Adams, Hassanain S Toma, Marie-Lyne Belair, Jennifer E Thorne, W Richard Green, Douglas A Jabs.   

Abstract

OBJECTIVE: To determine the clinical, histologic, and electroretinographic effects in the rabbit retina of escalating doses of two intravitreally delivered nonsteroidal anti-inflammatory drugs (NSAIDs): ketorolac and diclofenac.
METHODS: Right eyes received a single 0.1 mL injection of either ketorolac (500-6000 microg/0.1 mL) or diclofenac (300-1500 microg/0.1 mL) prepared in balanced salt solution (BSS). Left eyes served as controls and received BSS. Dark- and light-adapted electroretinograms (ERG) were obtained at baseline and 4 and 8 weeks postinjection. Enucleated eyes were examined histologically.
RESULTS: Ophthalmic examinations demonstrated no signs of intraocular inflammation or retinal toxicity. Intraocular pressure measurements remained similar between NSAID injected and control eyes. Histologic and ERG studies of eyes injected with 6000 microg ketorolac and >or=500 microg diclofenac demonstrated toxicity. In contrast, doses up to 3000 microg ketorolac demonstrated enhanced b-wave amplitude responses. Delayed drug toxicity was observed for the highest doses of both NSAIDs.
CONCLUSIONS: Intravitreal 3000 microg ketorolac and 300 microg diclofenac were nontoxic in this animal study, and may offer an effective and safer alternative to intravitreal corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398362     DOI: 10.1097/IAE.0b013e31815e98a5

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  11 in total

1.  The safety, pharmacokinetics, and efficacy of intraocular celecoxib.

Authors:  Stephen J Kim; Hassanain Toma; Rohan Shah; Uday B Kompella; Sunil K Vooturi; Jinsong Sheng
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-10       Impact factor: 4.799

2.  Novel Approaches for Retinal Drug and Gene Delivery.

Authors:  Stephen J Kim
Journal:  Transl Vis Sci Technol       Date:  2014-10-03       Impact factor: 3.283

3.  Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial.

Authors:  Masoud Soheilian; Saeed Karimi; Alireza Ramezani; Talieh Montahai; Mehdi Yaseri; Roham Soheilian; Gholam A Peyman
Journal:  Int Ophthalmol       Date:  2014-07-19       Impact factor: 2.031

4.  Evaluation of potential retinal toxicity of adalimumab (Humira).

Authors:  Miltiadis Tsilimbaris; Vasilios F Diakonis; Irini Naoumidi; Spyridon Charisis; Iraklis Kritikos; George Chatzithanasis; Thekla Papadaki; Sotiris Plainis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-03-19       Impact factor: 3.117

5.  Influence of dosage form on the intravitreal pharmacokinetics of diclofenac.

Authors:  Chandrasekar Durairaj; Stephen J Kim; Henry F Edelhauser; Jaymin C Shah; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-10       Impact factor: 4.799

6.  Intravitreal diclofenac for refractory uveitic cystoid macular edema.

Authors:  Alireza Ramezani; Nassim Fard Esmaeilpour; Armen Eskandari; Zahra Rabbanikhah; Roham Soheilian; Masoud Soheilian
Journal:  J Ophthalmic Vis Res       Date:  2013-01

7.  Suprachoroidal injection of ketorolac tromethamine does not cause retinal damage.

Authors:  Sumeng Liu; Wu Liu; Yaling Ma; Kegao Liu; Meizi Wang
Journal:  Neural Regen Res       Date:  2012-12-15       Impact factor: 5.135

8.  Solid Lipid Nanoparticles Improve the Diclofenac Availability in Vitreous after Intraocular Injection.

Authors:  Mojtaba Abrishami; Majid Abrishami; Asma Mahmoudi; Navid Mosallaei; Mohammad Vakili Ahrari Roodi; Bizhan Malaekeh-Nikouei
Journal:  J Drug Deliv       Date:  2016-10-10

9.  Intravitreal ketorolac for the treatment of chronic cystoid macular edema after cataract surgery.

Authors:  Miltiadis K Tsilimbaris; Chrysanthi Tsika; George D Kymionis
Journal:  Ther Clin Risk Manag       Date:  2016-02-12       Impact factor: 2.423

10.  Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction.

Authors:  Ester Carreño; Alejandro Portero; David J Galarreta; José M Herreras
Journal:  Clin Ophthalmol       Date:  2012-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.